ProCE Banner Activity

CITADEL-203 Phase II Study of the PI3Kδ Inhibitor Parsaclisib in Patients With Relapsed/Refractory Follicular Lymphoma

Slideset Download
Conference Coverage
Results from this trial showed that parsaclisib conferred rapid and durable responses in most patients with R/R FL, with a manageable safety profile.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation